Peripheral blood stem cell transplantation for breast cancer patients with bone marrow metastases using GM-CSF priming.
Twenty-seven patients with metastastic breast cancer to the bone marrow underwent successful collection of peripheral blood progenitor cells (PBPC) following GM-CSF cytokine priming and were engrafted following courses of high-dose chemotherapy.  Myeloid engraftment was observed in a median of 12 days, with a range of 8-29 days.  The cell dose infused correlated, although weakly, with days to engraftment, although assays of CFU-GM and CD34+ cells did not, suggesting refinement in such assays is needed.  The failure to observe complete remission of the tumor suggests alternative chemotherapy regimens should be investigated.
Hester
J P
JP
Department of Hematology, Division of Medicine, University of Texas, M.D. Anderson Cancer Center, Houston 77030.
Wallerstein
R O
RO
D000328:Adult; D016913:Blood Component Transfusion / Q000379:methods*; D001853:Bone Marrow; D001943:Breast Neoplasms / Q000628:therapy*; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D014182:Transplantation, Autologous